Verona Pharma PLC Director/PDMR Shareholding (5346N)

TIDMVRP

RNS Number : 5346N

Verona Pharma PLC

18 May 2015

Verona Pharma plc

("Verona Pharma" or the "Company")

Director Dealings

18 May 2015, Cardiff - Verona Pharma plc (AIM: VRP) today received notification that on 15 and 18 May 2015 Directors of the Company purchased ordinary shares of 0.1 pence each of the Company ("Ordinary Shares"). The details of the trades are shown in the table below.

 
                        Ordinary                                                As a % of the 
                         Shares                   Average     Total interest     total share 
 Director               Purchased      Date       Price (p)    in the Company      capital 
--------------------  -----------  -----------  -----------  ----------------  -------------- 
 Dr. David Ebsworth     300,000     18/05/2015      3.50         3,579,774          0.35% 
 Dr. Jan-Anders 
  Karlsson              135,000     15/05/2015      3.40         2,870,000          0.28% 
 Biresh Roy             150,000     18/05/2015      3.50          900,000           0.09%

-Ends-

For further information please contact:

 
 Verona Pharma plc            Tel: +44 (0) 20 3283 4200 
 Jan-Anders Karlsson, CEO 
 
 N+1 Singer                   Tel: +44 (0)20 7496 3000 
 Aubrey Powell / Jen Boorer 
 
 FTI Consulting               Tel: +44 (0)20 3727 1000 
 Julia Phillips / Simon 
  Conway

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSSFIFDAFISEDI

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024